News Release

Journal Article Cites AlbuSorb™ in Study of Intestinal Microbiota and Systemic Immunity

MONMOUTH JUNCTION, NJ, August 21, 2023 -- Biotech Support Group reports on a recent journal article using AlbuSorb™ to determine the how Albumin buffers the inflammatory impact of glycoconjugates derived from intestinal Firmicute cell walls.

The citation is:

Jordan, Christine KI, et al. "Symbiotic Firmicutes establish mutualism with the host via innate tolerance and resistance to control systemic immunity." Cell Host & Microbe (2023).

The intestinal microbiota regulates immunity across organ systems. Which symbionts control systemic immunity, the mechanisms they use, and how they avoid widespread inflammatory damage are unclear. Despite systemic penetration of Firmicutes, immune homeostasis is maintained through feedback control whereby macrophages clear polymeric glycoconjugates from peripheral tissues. Smaller glycoconjugates evading this clearance mechanism are tolerated through sequestration by albumin, which acts as an inflammatory buffer constraining their immunological impact. To determine this, the article states, “AlbuSorb (Biotech Support Group) was used to deplete albumin from mouse plasma as per manufacturer instructions.” “We found that complete human and murine plasma activated our NOD2, TLR2, and TLR4 reporter cells and that post-albumin depletion, plasma from both species activated reporter cells less potently (Figure), indicating that albumin sequesters circulating cell wall glycoconjugates.” The authors conclude that without these resistance and tolerance mechanisms, Firmicutes drive catastrophic organ damage and cachexia via IL-1b. This reveals how Firmicutes are safely assimilated into systemic immunity to protect against infection without threatening host viability.

“This reference shows that AlbuSorb™ is very selective for depleting albumin so that cell response with and without Albumin can be examined. Also, as our bead technology does not rely on immuno-affinity, it works for all species; mice in this example.”, states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information visit: AlbuSorb™ at
http://www.biotechsupportgroup.com/AlbuSorb-Albumin-Depletion-Kit-p/a185.htm

For more information on our complete line of Albumin & IgG Removal, visit:

https://www.biotechsupportgroup.com/Albumin-Removal-s/307.htm

Keywords

Intestinal Firmicutes, Albumin Removal, AlbuSorb™, systemic immunity

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

Contact:

Matthew Kuruc 732-274-2866

mkuruc@biotechsupportgroup.com